» Articles » PMID: 21272751

Antihypertensive Efficacy of Hydrochlorothiazide As Evaluated by Ambulatory Blood Pressure Monitoring: a Meta-analysis of Randomized Trials

Overview
Date 2011 Jan 29
PMID 21272751
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The purpose of this study was to evaluate the antihypertensive efficacy of hydrochlorothiazide (HCTZ) by ambulatory blood pressure (BP) monitoring.

Background: HCTZ is the most commonly prescribed antihypertensive drug worldwide. More than 97% of all HCTZ prescriptions are for 12.5 to 25 mg per day. The antihypertensive efficacy of HCTZ by ambulatory BP monitoring is less well defined.

Methods: A systematic review was made using Medline, Cochrane, and Embase for all the randomized trials that assessed 24-h BP with HCTZ in comparison with other antihypertensive drugs.

Results: Fourteen studies of HCTZ dose 12.5 to 25 mg with 1,234 patients and 5 studies of HCTZ dose 50 mg with 229 patients fulfilled the inclusion criteria. The decrease in 24-h BP with HCTZ dose 12.5 to 25 mg was systolic 6.5 mm Hg (95% confidence interval: 5.3 to 7.7 mm Hg) and diastolic 4.5 mm Hg (95% confidence interval: 3.1 to 6.0 mm Hg) and was inferior compared with the 24-h BP reduction of angiotensin-converting enzyme inhibitors (mean BP reduction 12.9/7.7 mm Hg; p < 0.003), angiotensin-receptor blockers (mean BP reduction 13.3/7.8 mm Hg; p < 0.001), beta-blockers (mean BP reduction 11.2/8.5 mm Hg; p < 0.00001), and calcium antagonists (mean BP reduction 11.0/8.1 mm Hg; p < 0.05). There was no significant difference in both systolic (p = 0.30) and diastolic (p = 0.15) 24-h BP reduction between HCTZ 12.5 mg (5.7/3.3 mm Hg) and HCTZ 25 mg (7.6/5.4 mm Hg). However, with HCTZ 50 mg, the reduction in 24-h BP was significantly higher (12.0/5.4 mm Hg) and was comparable to that of other agents.

Conclusions: The antihypertensive efficacy of HCTZ in its daily dose of 12.5 to 25 mg as measured in head-to-head studies by ambulatory BP measurement is consistently inferior to that of all other drug classes. Because outcome data at this dose are lacking, HCTZ is an inappropriate first-line drug for the treatment of hypertension.

Citing Articles

Recent advances in anticancer mechanisms of molecular glue degraders: focus on RBM39-dgrading synthetic sulfonamide such as indisulam, E7820, tasisulam, and chloroquinoxaline sulfonamide.

Jang J, Kim J, Lee T Genes Genomics. 2024; 46(12):1345-1361.

PMID: 39271535 DOI: 10.1007/s13258-024-01565-z.


Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials.

Chalmers J, Mourad J, Brzozowska-Villatte R, De Champvallins M, Mancia G J Hypertens. 2023; 41(3):508-515.

PMID: 36633311 PMC: 9894155. DOI: 10.1097/HJH.0000000000003368.


White matter hyperintensities in Burning Mouth Syndrome assessed according to the Age-Related White Matter Changes scale.

Adamo D, Canfora F, Calabria E, Coppola N, Leuci S, Pecoraro G Front Aging Neurosci. 2022; 14:923720.

PMID: 36118686 PMC: 9475000. DOI: 10.3389/fnagi.2022.923720.


Renal denervation in the antihypertensive arsenal - knowns and known unknowns.

Messerli F, Bavishi C, Brguljan J, Burnier M, Dobner S, Elijovich F J Hypertens. 2022; 40(10):1859-1875.

PMID: 36052518 PMC: 10010701. DOI: 10.1097/HJH.0000000000003171.


Burning Fog: Cognitive Impairment in Burning Mouth Syndrome.

Canfora F, Calabria E, Cuocolo R, Ugga L, Buono G, Marenzi G Front Aging Neurosci. 2021; 13:727417.

PMID: 34475821 PMC: 8406777. DOI: 10.3389/fnagi.2021.727417.